HDAC6 Inhibitor Patent - 2-Isoindol-1,3,4-Oxadiazole Derivatives

The European Patent Office published patent application EP4034536A1 filed by Takeda Pharmaceutical Company Limited covering 2-Isoindol-1,3,4-Oxadiazole compounds as histone deacetylase 6 (HDAC6) inhibitors. The compounds are classified under IPC C07D 413/04 with potential neurological applications indicated by A61P 25/28. The application designates all relevant European contracting states including DE, FR, GB, IT, ES, and others.

This is a patent publication notice with no compliance requirements for third parties. Pharmaceutical companies developing HDAC6 inhibitors or competing compounds should review the claims for potential freedom-to-operate concerns. The patent, once granted, will provide Takeda with exclusivity for the claimed compounds in designated European states.